Changchun High-tech's "new drug for treating developmental disorders in boys" causes stock price to soar, company response: project is still in early stages.

After hitting the limit up on February 25, on February 26, the stock price of Changchun High-tech continued to rise, with a weekly increase of over 12% so far. On the news front, the clinical trial application for GenSci141 ointment of Changchun Gold Saige Pharmaceutical Co., Ltd., a subsidiary of Changchun High-tech, has been approved, with indications for improving pediatric micropenis caused by various reasons. Data shows that this is the world's first drug targeting pediatric micropenis. It is noted that there is limited literature on pediatric micropenis, and there is controversy globally regarding incidence, classification, surgical indications, and surgical age. This also makes the market pay special attention to the clinical progress of GenSci141 ointment. On February 26, Changchun High-tech stated to reporters that the project is still in the early stages and there is currently no information available for external communication.